Do genetic polymorphisms alter patient response to inhaled bronchodilators?

Bibliography

• Moffatt MF, Kabesch M, Liang L, et al. Genetic variants regulating ORMDL3 expression contribute to the risk of childhood asthma. Nature 2007;448:470-3
   PubMed Web of Science ®Google Scholar
• Himes BE, Hunninghake GM, Baurley JW, et al. Genome-wide association analysis identifies PDE4D as an asthma-susceptibility gene. Am J Hum Genet 2009;84:581-93
   PubMed Web of Science ®Google Scholar
• Hancock DB, Romieu I, Shi M, et al. Genome-wide association study implicates chromosome 9q21.31 as a susceptibility locus for asthma in mexican children. PLoS Genet 2009;5:e1000623
   PubMed Web of Science ®Google Scholar
• Mathias RA, Grant AV, Rafaels N, et al. A genome-wide association study on African-ancestry populations for asthma. J Allergy Clin Immunol 2010;125:336-46
   PubMed Web of Science ®Google Scholar
• Sleiman PM, Flory J, Imielinski M, et al. Variants of DENND1B associated with asthma in children. N Engl J Med 2010;362:36-44
   PubMed Web of Science ®Google Scholar
• Moffatt MF, Gut IG, Demenais F, et al. A large-scale, consortium-based genomewide association study of asthma. N Engl J Med 2010;363:1211-21
   PubMed Web of Science ®Google Scholar
• Haldar P, Pavord ID, Shaw DE, et al. Cluster analysis and clinical asthma phenotypes. Am J Respir Crit Care Med 2008;178:218-24
   PubMed Web of Science ®Google Scholar
• Moore WC, Meyers DA, Wenzel SE, et al. Identification of asthma phenotypes using cluster analysis in the Severe Asthma Research Program. Am J Respir Crit Care Med 2010;181:315-23
   PubMed Web of Science ®Google Scholar
• Fitzpatrick AM, Teague WG, Meyers DA, et al. Heterogeneity of severe asthma in childhood: confirmation by cluster analysis of children in the National Institutes of Health/National Heart, Lung, and Blood Institute Severe Asthma Research Program. J Allergy Clin Immunol 2011;127:382-9; e1-13
   PubMed Web of Science ®Google Scholar
• Sutherland ER, Goleva E, King TS, et al. Cluster analysis of obesity and asthma phenotypes. PLoS One 2012;7:e36631
   PubMed Web of Science ®Google Scholar
• Patrawalla P, Kazeros A, Rogers L, et al. Application of the asthma phenotype algorithm from the Severe Asthma Research Program to an urban population. PLoS One 2012;7:e44540
   PubMedGoogle Scholar
• Kim TB, Jang AS, Kwon HS, et al. Identification of asthma clusters in two independent Korean adult asthma cohorts. Eur Respir J 2013;41(6):1308-14
   PubMed Web of Science ®Google Scholar
• Ober C, Vercelli D. Gene-environment interactions in human disease: nuisance or opportunity? Trends Genet 2011;27:107-15
   PubMed Web of Science ®Google Scholar
• Asher MI, Montefort S, Bjorksten B, et al. Worldwide time trends in the prevalence of symptoms of asthma, allergic rhinoconjunctivitis, and eczema in childhood: ISAAC Phases One and Three repeat multicountry cross-sectional surveys. Lancet 2006;368:733-43
   PubMed Web of Science ®Google Scholar
• Masoli M, Fabian D, Holt S, Beasley R. The global burden of asthma: executive summary of the GINA Dissemination Committee report. Allergy 2004;59:469-78
   PubMed Web of Science ®Google Scholar
• Expert Panel Report 3 (EPR-3): guidelines for the diagnosis and management of asthma-summary report 2007. J Allergy Clin Immunol 2007;120:S94-138
   PubMed Web of Science ®Google Scholar
• Cazzola M, Page CP, Calzetta L, Matera MG. Pharmacology and therapeutics of bronchodilators. Pharmacol Rev 2012;64:450-504
   PubMed Web of Science ®Google Scholar
• Lohse MJ. Molecular mechanisms of membrane receptor desensitization. Biochim Biophys Acta 1993;1179:171-88
   PubMed Web of Science ®Google Scholar
• Hankinson JL, Odencrantz JR, Fedan KB. Spirometric reference values from a sample of the general U.S. population. Am J Respir Crit Care Med 1999;159:179-87
   PubMed Web of Science ®Google Scholar
• Tse SM, Tantisira K, Weiss ST. The pharmacogenetics and pharmacogenomics of asthma therapy. Pharmacogenomics J 2011;11:383-92
   PubMed Web of Science ®Google Scholar
• Thomsen SF, van der Sluis S, Kyvik KO, et al. Estimates of asthma heritability in a large twin sample. Clin Exp Allergy 2010;40:1054-61
   PubMed Web of Science ®Google Scholar
• Klimentidis YC, Vazquez AI, de Los Campos G, et al. Heritability of pulmonary function estimated from pedigree and whole-genome markers. Front Genet 2013;4:174
   Google Scholar
• McGeachie MJ, Wu AC, Chang HH, et al. Predicting inhaled corticosteroid response in asthma with two associated SNPs. Pharmacogenomics J 2013;13:306-11
   PubMed Web of Science ®Google Scholar
• Crompton G. A brief history of inhaled asthma therapy over the last fifty years. Prim Care Respir J 2006;15:326-31
   PubMedGoogle Scholar
• Ortega VE, Peters SP. Beta-2 adrenergic agonists: focus on safety and benefits versus risks. Curr Opin Pharmacol 2010;10:246-53
   PubMed Web of Science ®Google Scholar
• Drazen JM, Israel E, Boushey HA, et al. Comparison of regularly scheduled with as-needed use of albuterol in mild asthma. Asthma Clinical Research Network. N Engl J Med 1996;335:841-7
   PubMed Web of Science ®Google Scholar
• Spitzer WO, Suissa S, Ernst P, et al. The use of beta-agonists and the risk of death and near death from asthma. N Engl J Med 1992;326:501-6
   PubMed Web of Science ®Google Scholar
• Suissa S, Ernst P, Spitzer WO. Asthma deaths in New Zealand. BMJ 1992;305:889; author reply 90
   PubMedGoogle Scholar
• Lazarus SC, Boushey HA, Fahy JV, et al. Long-acting beta2-agonist monotherapy vs continued therapy with inhaled corticosteroids in patients with persistent asthma: a randomized controlled trial. JAMA 2001;285:2583-93
   PubMed Web of Science ®Google Scholar
• McIvor RA, Pizzichini E, Turner MO, et al. Potential masking effects of salmeterol on airway inflammation in asthma. Am J Respir Crit Care Med 1998;158:924-30
   PubMed Web of Science ®Google Scholar
• Salpeter SR, Buckley NS, Ormiston TM, Salpeter EE. Meta-analysis: effect of long-acting beta-agonists on severe asthma exacerbations and asthma-related deaths. Ann Intern Med 2006;144:904-12
   PubMed Web of Science ®Google Scholar
• Lemanske RF Jr, Sorkness CA, Mauger EA, et al. Inhaled corticosteroid reduction and elimination in patients with persistent asthma receiving salmeterol: a randomized controlled trial. JAMA 2001;285:2594-603
   PubMed Web of Science ®Google Scholar
• Subbarao P, Ratjen F. Beta2-agonists for asthma: the pediatric perspective. Clin Rev Allergy Immunol 2006;31:209-18
   PubMed Web of Science ®Google Scholar
• Bisgaard H, Szefler S. Long-acting beta2 agonists and paediatric asthma. Lancet 2006;367:286-8
   PubMed Web of Science ®Google Scholar
• Verberne AA, Frost C, Roorda RJ, et al. One year treatment with salmeterol compared with beclomethasone in children with asthma. The Dutch Paediatric Asthma Study Group. Am J Respir Crit Care Med 1997;156:688-95
   PubMed Web of Science ®Google Scholar
• Mann M, Chowdhury B, Sullivan E, et al. Serious asthma exacerbations in asthmatics treated with high-dose formoterol. Chest 2003;124:70-4
   PubMed Web of Science ®Google Scholar
• Castle W, Fuller R, Hall J, Palmer J. Serevent nationwide surveillance study: comparison of salmeterol with salbutamol in asthmatic patients who require regular bronchodilator treatment. BMJ 1993;306:1034-7
   PubMed Web of Science ®Google Scholar
• Cates CJ, Cates MJ. Regular treatment with salmeterol for chronic asthma: serious adverse events. Cochrane Database Syst Rev 2008;CD006363
   Google Scholar
• Nelson HS, Weiss ST, Bleecker ER, et al. The Salmeterol Multicenter Asthma Research Trial: a comparison of usual pharmacotherapy for asthma or usual pharmacotherapy plus salmeterol. Chest 2006;129:15-26
   PubMed Web of Science ®Google Scholar
• FDA Drug Safety Communication: New safety requirements for long-acting inhaled asthma medications called Long-Acting Beta-Agonists (LABAs). 2010. Available from: www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/ucm200776.htm [Accessed 16 June 2014]; Referenced June 24, 2014
   Google Scholar
• Kramer JB. Balancing the benefits and risks of inhaled long-acting beta-agonists - the influence of values. N Engl J Med 2009;360:1592-5
   PubMed Web of Science ®Google Scholar
• Chowdhury BA, Dal Pan G. The FDA and safe use of long-acting beta-agonists in the treatment of asthma. N Engl J Med 2010;362:1169-71
   PubMed Web of Science ®Google Scholar
• Rodrigo GJ, Moral VP, Marcos LG, Castro-Rodriguez JA. Safety of regular use of long-acting beta agonists as monotherapy or added to inhaled corticosteroids in asthma. A systematic review. Pulm Pharmacol Ther 2009;22:9-19
   PubMed Web of Science ®Google Scholar
• Bateman E, Nelson H, Bousquet J, et al. Meta-analysis: effects of adding salmeterol to inhaled corticosteroids on serious asthma-related events. Ann Intern Med 2008;149:33-42
   PubMed Web of Science ®Google Scholar
• Ortega VE, Wechsler ME. Asthma pharmacogenetics: responding to the call for a personalized approach. Curr Opin Allergy Clin Immunol 2013;13:399-409
   PubMed Web of Science ®Google Scholar
• Salpeter SR. An update on the safety of long-acting beta-agonists in asthma patients using inhaled corticosteroids. Expert Opin Drug Saf 2010;9:407-19
   PubMed Web of Science ®Google Scholar
• Sears MR. Safe use of long-acting beta-agonists: what have we learnt? Expert Opin Drug Saf 2011;10:767-78
   PubMed Web of Science ®Google Scholar
• Hawkins GA, Tantisira K, Meyers DA, et al. Sequence, haplotype, and association analysis of ADRbeta2 in a multiethnic asthma case-control study. Am J Respir Crit Care Med 2006;174:1101-9
   PubMed Web of Science ®Google Scholar
• Green SA, Turki J, Innis M, Liggett SB. Amino-terminal polymorphisms of the human beta 2-adrenergic receptor impart distinct agonist-promoted regulatory properties. Published erratum appears in Biochemistry 1994 Nov 29;33(47):14368 Biochemistry 1994;33:9414-19
   PubMed Web of Science ®Google Scholar
• Green SA, Turki J, Bejarano P, et al. Influence of beta 2-adrenergic receptor genotypes on signal transduction in human airway smooth muscle cells. Am J Respir Cell Mol Biol 1995;13:25-33
   PubMed Web of Science ®Google Scholar
• Liggett SB. Polymorphisms of the beta2-adrenergic receptor and asthma. Am J Respir Crit Care Med 1997;156:S156-S62
   PubMed Web of Science ®Google Scholar
• Martinez FD, Graves PE, Baldini M, et al. Association between genetic polymorphisms of the beta2-adrenoceptor and response to albuterol in children with and without a history of wheezing. J Clin Invest 1997;100:3184-8
   PubMed Web of Science ®Google Scholar
• Lima JJ, Thomason DB, Mohamed MH, et al. Impact of genetic polymorphisms of the beta2-adrenergic receptor on albuterol bronchodilator pharmacodynamics. Clin Pharmacol Ther 1999;65:519-25
   PubMed Web of Science ®Google Scholar
• Choudhry S, Ung N, Avila PC, et al. Pharmacogenetic differences in response to albuterol between Puerto Ricans and Mexicans with asthma. Am J Respir Crit Care Med 2005;171:563-70
   PubMed Web of Science ®Google Scholar
• Drysdale CM, McGraw DW, Stack CB, et al. Complex promoter and coding region beta 2-adrenergic receptor haplotypes alter receptor expression and predict in vivo responsiveness [In Process Citation]. Proc Natl Acad Sci USA 2000;97:10483-8
   PubMed Web of Science ®Google Scholar
• Silverman EK, Kwiatkowski DJ, Sylvia JS, et al. Family-based association analysis of beta2-adrenergic receptor polymorphisms in the childhood asthma management program. J Allergy Clin Immunol 2003;112:870-6
   PubMed Web of Science ®Google Scholar
• Taylor DR, Epton MJ, Kennedy MA, et al. Bronchodilator response in relation to beta2-adrenoceptor haplotype in patients with asthma. Am J Respir Crit Care Med 2005;172:700-3
   PubMed Web of Science ®Google Scholar
• Hall IP, Blakey JD, Al Balushi KA, et al. Beta2-adrenoceptor polymorphisms and asthma from childhood to middle age in the British. 1958 birth cohort: a genetic association study. Lancet 2006;368:771-9
   PubMed Web of Science ®Google Scholar
• Tsai HJ, Shaikh N, Kho JY, et al. Beta 2-adrenergic receptor polymorphisms: pharmacogenetic response to bronchodilator among African American asthmatics. Hum Genet 2006;119:547-57
   PubMed Web of Science ®Google Scholar
• Israel E, Chinchilli VM, Ford JG, et al. Use of regularly scheduled albuterol treatment in asthma: genotype-stratified, randomised, placebo-controlled cross-over trial. Lancet 2004;364:1505-12
   PubMed Web of Science ®Google Scholar
• Hancox RJ, Sears MR, Taylor DR. Polymorphism of the beta2-adrenoceptor and the response to long-term beta2-agonist therapy in asthma. Eur Respir J 1998;11:589-93
   PubMed Web of Science ®Google Scholar
• Taylor DR, Drazen JM, Herbison GP, et al. Asthma exacerbations during long term beta agonist use: influence of beta(2) adrenoceptor polymorphism. Thorax 2000;55:762-7
   PubMed Web of Science ®Google Scholar
• Wechsler ME, Lehman E, Lazarus SC, et al. beta-Adrenergic receptor polymorphisms and response to salmeterol. Am J Respir Crit Care Med 2006;173:519-26
   PubMed Web of Science ®Google Scholar
• Lee DK, Currie GP, Hall IP, et al. The arginine-16 beta2-adrenoceptor polymorphism predisposes to bronchoprotective subsensitivity in patients treated with formoterol and salmeterol. Br J Clin Pharmacol 2004;57:68-75
   PubMed Web of Science ®Google Scholar
• Bleecker ER, Postma DS, Lawrance RM, et al. Effect of ADRB2 polymorphisms on response to longacting beta2-agonist therapy: a pharmacogenetic analysis of two randomised studies. Lancet 2007;370:2118-25
   PubMed Web of Science ®Google Scholar
• Bleecker ER, Nelson HS, Kraft M, et al. Beta2-receptor polymorphisms in patients receiving salmeterol with or without fluticasone propionate. Am J Respir Crit Care Med 2010;181:676-87
   PubMed Web of Science ®Google Scholar
• Wechsler ME, Kunselman SJ, Chinchilli VM, et al. Effect of beta2-adrenergic receptor polymorphism on response to longacting beta2 agonist in asthma (LARGE trial): a genotype-stratified, randomised, placebo-controlled, crossover trial. Lancet 2009;374:1754-64
   PubMed Web of Science ®Google Scholar
• Bonini M, Permaul P, Kulkarni T, et al. Loss of salmeterol bronchoprotection against exercise in relation to ADRB2 Arg16Gly polymorphism and exhaled nitric oxide. Am J Respir Crit Care Med 2013;188:1407-12
   PubMed Web of Science ®Google Scholar
• Ambrose HJ, Lawrance RM, Cresswell CJ, et al. Effect of beta2-adrenergic receptor gene (ADRB2) 3′ untranslated region polymorphisms on inhaled corticosteroid/long-acting beta2-adrenergic agonist response. Respir Res 2012;13:37
   PubMed Web of Science ®Google Scholar
• Bisgaard H. Effect of long-acting beta2 agonists on exacerbation rates of asthma in children. Pediatr Pulmonol 2003;36:391-8
   PubMed Web of Science ®Google Scholar
• Verberne AA, Frost C, Duiverman EJ, et al. Addition of salmeterol versus doubling the dose of beclomethasone in children with asthma. The Dutch Asthma Study Group. Am J Respir Crit Care Med 1998;158:213-19
   PubMed Web of Science ®Google Scholar
• Palmer CN, Lipworth BJ, Lee S, et al. Arginine-16 beta2 adrenoceptor genotype predisposes to exacerbations in young asthmatics taking regular salmeterol. Thorax 2006;61:940-4
   PubMed Web of Science ®Google Scholar
• Zuurhout MJ, Vijverberg SJ, Raaijmakers JA, et al. Arg16 ADRB2 genotype increases the risk of asthma exacerbation in children with a reported use of long-acting beta2-agonists: results of the PACMAN cohort. Pharmacogenomics 2013;14:1965-71
   PubMed Web of Science ®Google Scholar
• Ortega VE, Hawkins GA, Moore WC, et al. Effect of rare variants in ADRB2 on risk of severe exacerbations and symptom control during longacting beta agonist treatment in a multiethnic asthma population: a genetic study. Lancet Respir Med 2014;2:204-13
   PubMed Web of Science ®Google Scholar
• Moore PE, Ryckman KK, Williams SM, et al. Genetic variants of GSNOR and ADRB2 influence response to albuterol in African-American children with severe asthma. Pediatr Pulmonol 2009;44:649-54
   PubMed Web of Science ®Google Scholar
• Choudhry S, Que LG, Yang Z, et al. GSNO reductase and beta2-adrenergic receptor gene-gene interaction: bronchodilator responsiveness to albuterol. Pharmacogenet Genomics 2010;20:351-8
   PubMed Web of Science ®Google Scholar
• Tantisira KG, Small KM, Litonjua AA, et al. Molecular properties and pharmacogenetics of a polymorphism of adenylyl cyclase type 9 in asthma: interaction between beta-agonist and corticosteroid pathways. Hum Mol Genet 2005;14:1671-7
   PubMed Web of Science ®Google Scholar
• Poon AH, Tantisira KG, Litonjua AA, et al. Association of corticotropin-releasing hormone receptor-2 genetic variants with acute bronchodilator response in asthma. Pharmacogenet Genomics 2008;18:373-82
   PubMed Web of Science ®Google Scholar
• Litonjua AA, Lasky-Su JA, Schneiter K, et al. ARG1 is a novel bronchodilator response gene: screening and replication in four asthma cohorts. Am J Respir Crit Care Med 2008;178(7):688-94
   PubMed Web of Science ®Google Scholar
• Duan QL, Gaume BR, Hawkins GA, et al. Regulatory haplotypes in ARG1 are associated with altered bronchodilator response. Am J Respir Crit Care Med 2011;183:449-54
   PubMed Web of Science ®Google Scholar
• Duan QL, Lasky-Su J, Himes BE, et al. A genome-wide association study of bronchodilator response in asthmatics. Pharmacogenomics J 2014;14(1):41-7
   PubMed Web of Science ®Google Scholar
• Himes BE, Jiang X, Hu R, et al. Genome-wide association analysis in asthma subjects identifies SPATS21 as a novel bronchodilator response gene. PLos Genet 2012;8(7):e1002824
   PubMed Web of Science ®Google Scholar
• Padhukasahasram B, Yang JJ, Levin AM, et al. Gene-based association identifies SPATA13-AS1 as a pharmacogenomic predictor of inhaled short-acting beta-agonist response in multiple population groups. Pharmacogenomics J 2014. [ Epub ahead of print]
   PubMed Web of Science ®Google Scholar
• Duan QL, Lasky-Su J, Himes BE, et al. A genome-wide association study of bronchodilator response in asthmatics. Pharmacogenomics J 2014;14:41-7
   PubMed Web of Science ®Google Scholar
• Drake KA, Torgerson DG, Gignoux CR, et al. A genome-wide association study of bronchodilator response in Latinos implicates rare variants. J Allergy Clin Immunol 2014;133:370-8; e15
   PubMed Web of Science ®Google Scholar
• Urban TJ. Whole-genome sequencing in pharmacogenetics. Pharmacogenomics 2013;14:345-8
   PubMed Web of Science ®Google Scholar
• Wu AC, Himes BE, Lasky-Su J, et al. Development of a Pharmacogenetic Predictive Test in asthma: proof of concept. Pharmacogenet Genomics 2010;20:86-93
   PubMed Web of Science ®Google Scholar